trending Market Intelligence /marketintelligence/en/news-insights/trending/gz58bkvgpbxh_qpllu5_za2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

US FDA grants Lupin tentative approval to market generic ulcer drug

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry

Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets


US FDA grants Lupin tentative approval to market generic ulcer drug

The U.S. FDA granted Lupin Ltd. tentative approval to market its balasalazide disodium tablets, a generic version of Salix Pharmaceutical Inc.'s Giazo.

The drug is meant for the treatment of ulcerative colitis in male patients above the age of 18 years.